Ms. Cristea Diana | Pharmaceutical | Best Researcher Award

Posted on by ScienceFather

Ms. Cristea Diana | Pharmaceutical | Best Researcher Award

Ms. Cristea Diana, Politehnica University of Bucharest, Romania

Diana Cristea is a dedicated Quality Control professional with expertise in ensuring product integrity in the pharmaceutical industry. She holds a Bachelor’s and Master’s degree in Medical Engineering and Pharmaceutical & Cosmetic Products from the University Politehnica of Bucharest. Diana has worked as a Quality Control Analyst and Supervisor at Rompharm Company, where she has led quality improvements, managed teams, and conducted training sessions. Her recent research in nanocomposites demonstrates her commitment to advancing pharmaceutical technology. Diana is an emerging leader in the field of quality control, with a focus on continuous improvement and regulatory compliance. πŸ†πŸ”¬πŸ“Š

Professional Profile:

Google Scholar

Summary of Suitability

Diana Cristea is an outstanding candidate for the Best Researcher Award due to her exceptional contributions to the pharmaceutical industry, with a focus on quality control, innovative nanotechnology research, and continuous professional development.

Education & Experience

  • Bachelor’s degree in Medical Engineering, University Politehnica of Bucharest (2017–2021) πŸŽ“
  • Master’s degree in Pharmaceutical & Cosmetic Products, University Politehnica of Bucharest (2021–2023) πŸŽ“
  • Quality Control Analyst, Rompharm Company, Otopeni (September 2021–October 2023) πŸ§ͺ
  • Quality Control Supervisor, Rompharm Company, Otopeni (October 2023–Present) πŸ§‘β€πŸ”¬

Professional Development

Diana Cristea is actively advancing her professional qualifications to enhance her expertise. She is currently enrolled in the Qualified Person Program at Carol Davila University of Medicine and Pharmacy, where she is gaining in-depth knowledge of pharmaceutical regulations and practices. Diana is also pursuing an ISO 9001 Certification with TUV Austria, aimed at further improving her skills in quality management systems. These qualifications will support her ability to lead in high-standard pharmaceutical and cosmetic product testing. πŸ“šπŸ‘©β€πŸ«πŸ› οΈ

Research Focus

Diana’s research focuses on pharmaceutical nanotechnology, specifically on the development of micafungin-loaded magnetite–salicylic acid–silica nanocomposites. She investigates methods to improve drug stability and biocompatibility using innovative techniques like vortex-mixing microfluidic systems. Her work has led to the creation of nanocomposites with sustained-release properties, providing potential advancements in drug delivery systems for fungal infections. Diana is passionate about nanomedicine and is committed to contributing to global health by enhancing pharmaceutical formulations. πŸ”¬πŸ’ŠπŸ§¬

Awards & Honors

  • ISO 9001 Certification, TUV Austria (2024) πŸ…
  • Qualified Person Program, Carol Davila University of Medicine and Pharmacy (2024) πŸŽ“
  • Research Publication, MDPI, Materials Journal (2024) πŸ“

Publication Top Notes:

Vortex-Mixing Microfluidic Fabrication of Micafungin-Loaded Magnetite–Salicylic Acid–Silica Nanocomposite with Sustained-Release Capacity πŸ§ͺπŸ’Š

 

Dr. Rahmuddin khan | Pharmaceutics Awards | Best Researcher Award

Posted on by ScienceFather

Dr. Rahmuddin khan | Pharmaceutics Awards | Best Researcher Award

Dr. Rahmuddin khan, jamia hamdard, India

Dr. Rahmuddin is a skilled pharmaceutics researcher specializing in nano-based drug delivery systems for topical diseases, with a primary focus on psoriasis. Currently affiliated with the Nanomedicine Lab at Jamia Hamdard, New Delhi, he has a rich background in developing functional excipients and enhancing drug solubility through novel formulations. His academic path, from a Bachelor’s to a Ph.D. in Pharmaceutics at Jamia Hamdard, has cultivated his expertise across several scientific domains. Rahmuddin’s research includes hands-on experience with regulatory safety, non-clinical assessments, and industry-sponsored projects involving fulvic acid-based nanoformulations. Known for his analytical thinking, scientific writing, and mentorship, he has published extensively in reputable journals, showcasing advancements in nanoemulsion gels for conditions like psoriasis and tuberculosis. His collaborative work with New Zealand Fulvic Acid Limited and Reckitt Benckiser demonstrates his commitment to bridging industry with academic research for innovative therapeutic solutions.

Professional Profile:

Google Scholar

Suitability for the Best Researcher Award:

Dr. Rahmuddin is a highly deserving candidate for the Best Researcher Award due to his significant contributions to the field of pharmaceutics, particularly in the area of nano-based drug delivery systems for topical diseases such as psoriasis. His innovative research focuses on enhancing drug solubility and improving the effectiveness of topical treatments through novel formulations, including nanoemulsion gels. Dr. Rahmuddin’s academic background, culminating in his Ph.D. from Jamia Hamdard, showcases his deep understanding of pharmaceutics and his dedication to advancing drug delivery systems. His work with industry collaborators like New Zealand Fulvic Acid Limited and Reckitt Benckiser demonstrates his ability to bridge the gap between academia and industry, driving practical solutions for complex medical challenges.

πŸŽ“Education :

Rahmuddin completed his entire academic journey in Pharmaceutics at Jamia Hamdard, New Delhi, earning his Ph.D. in 2023. His doctoral thesis, titled “Novel Functional Excipient Appended System for Psoriasis,” explored advanced nano-based drug delivery systems, aimed at enhancing topical treatments. Prior to his Ph.D., he completed his M.Pharm in 2018, where he focused on β€œExploration of Novel Peat-Sourced Fulvic Acid for Solubility Improvement of BCS Class II Drugs.” This research tackled the challenge of drug solubility by investigating natural compounds with pharmaceutical potential. He began his academic career with a B.Pharm in 2016 from the same institution, laying a solid foundation in pharmacy, pharmaceutics, and research methodologies. Throughout his academic journey, he developed strong technical expertise in drug formulation, excipient selection, and nano-delivery systems, equipping him with the necessary skills to innovate within the field of targeted drug delivery.

🏒Experience :

Rahmuddin’s professional experience spans academia, industry collaboration, and regulatory roles. His most recent role as a Consumer Safety Assistant at Reckitt Benckiser (May–Oct 2024) involved ensuring regulatory compliance and conducting non-clinical safety assessments. During his M.Pharm, he worked as a Research Associate on an industry-sponsored project with New Zealand Fulvic Acid Limited, focused on fulvic acid-based nanoformulations, an experience that honed his skills in drug delivery for pharmaceutical applications. His extensive research as a Ph.D. candidate at Jamia Hamdard (Dec 2018–Nov 2023) allowed him to specialize in topical drug delivery systems and provided opportunities to mentor M.Pharm and Ph.D. students. He has gained substantial laboratory experience, working with equipment like UV spectrophotometers, HPLC, tablet compression machines, and dissolution apparatuses, making him proficient in both theoretical knowledge and practical skills essential for pharmaceutical research.

πŸ…Awards and Honors :

Rahmuddin has received recognition for his work through various academic and industry-sponsored projects. Notably, his collaboration with New Zealand Fulvic Acid Limited on a project involving fulvic acid-based nanoformulations earned him significant acclaim, highlighting his contributions to innovative drug delivery research. His dedication to advancing drug solubility and effectiveness has been acknowledged within the academic community, where he has been a mentor and guide for students exploring solutions for complex diseases like psoriasis and tuberculosis. His publications in reputable journals, featuring targeted treatments and polysaccharide-based nano-drug delivery vehicles, showcase his commitment to expanding the applications of nano-based therapies. Through his professional experience and academic guidance, Rahmuddin continues to impact the field of pharmaceutics, bridging industry needs with academic insights to support advancements in the treatment of chronic diseases.

πŸ”¬Research Focus :

Rahmuddin’s research centers on the development of nano-based drug delivery systems for topical treatments, especially focusing on diseases like psoriasis. His work includes the creation of innovative excipients and nanoemulsion gels that improve drug solubility and targeted delivery, addressing issues faced with conventional formulations. In collaboration with New Zealand Fulvic Acid Limited, he has explored the pharmaceutical potential of fulvic acid for enhancing drug solubility, contributing to advancements in drug delivery systems. His technical skills encompass various analytical tools, including HPLC, UV spectrophotometry, and tablet compression machines, allowing him to design and assess complex formulations. Rahmuddin’s research portfolio spans a broad range of disease models beyond psoriasis, including acne and tuberculosis, exemplifying his commitment to leveraging nanotechnology for enhanced therapeutic outcomes. His contributions to scientific literature and mentorship to upcoming researchers further solidify his role as an innovative force in pharmaceutics.

Publication Top Notes:

  • “In vitro and in vivo investigation of a dual-targeted nanoemulsion gel for the amelioration of psoriasis”
    • Citations: 24
  • “A pharmaco-technical investigation of thymoquinone and peat-sourced fulvic acid nanoemulgel: a combination therapy”
    • Citations: 16
  • “Pharmacokinetic evaluation of fulvic acid-ketoconazole complexes: A validation and line extension study”
    • Citations: 7
  • “Neuroprotective effects of trigonelline in kainic acid-induced epilepsy: Behavioral, biochemical, and functional insights”
    • Citations: 5
  • “COVID-19 pandemic challenges and their management: A review of medicines, vaccines, patents and clinical trials with emphasis on psychological health issues”
    • Citations: 4

 

 

 

Prof. Franciska Erdo | Drug delivery Award | Best Researcher Award

Posted on by ScienceFather

Prof. Franciska Erdo | Drug delivery Award | Best Researcher Award

Prof. Franciska Erdo , PΓ‘zmΓ‘ny PΓ©ter Catholic University , Hungary

Franciska VidΓ‘nΓ© Dr. ErdΕ‘, born on May 28, 1964, in Budapest, is a distinguished full professor and lab head at PΓ‘zmΓ‘ny PΓ©ter Catholic University, Faculty of Information Technology and Bionics. She holds a PhD in pharmacology from Semmelweis University and has extensive experience in both academic and research institutions, including the University of Tours, CharitΓ© Medizinische UniversitΓ€t in Berlin, and the Max-Planck Institute in Cologne. Her research focuses on drug research and development, evidenced by her numerous fellowships and scholarships. She has supervised over 31 graduate students and postdoctoral fellows and has been recognized for her teaching excellence. Dr. ErdΕ‘ has also contributed significantly to scientific literature and education, particularly in the fields of molecular bionics and biomedical innovation.

Professional Profile:

Orcid

Education:

Franciska VidΓ‘nΓ© Dr. ErdΕ‘ earned her MSc in Pharmacy from Semmelweis University in 1987, graduating with top grades. She continued her education at the same institution, achieving a University Doctor degree in Pharmacology with summa cum laude honors in 1994. In 1997, she completed her PhD in Pharmacology, also with summa cum laude distinction, at Semmelweis University, Faculty of Pharmacy. Most recently, in 2019, she received her habilitation from PΓ‘zmΓ‘ny PΓ©ter Catholic University, Faculty of Information Technology and Bionics.

Work Experience:

Franciska VidΓ‘nΓ© Dr. ErdΕ‘ has held numerous esteemed positions throughout her career. Since 2024, she has been serving as a Full Professor and Lab Head at PΓ‘zmΓ‘ny PΓ©ter Catholic University, Faculty of Information Technology and Bionics. Prior to this, from 2019 to 2024, she was an Associate Professor and Lab Head at the same institution. She was also a Guest Researcher at the University of Tours, France, in 2022. From 2014 to 2019, she worked as a Senior Research Fellow and Lab Head at PΓ‘zmΓ‘ny PΓ©ter Catholic University. Her earlier roles include serving as a Senior Research Fellow and Lab Head at SOLVO Biotechnology from 2007 to 2014, and holding a scientific scholarship at CharitΓ© Medizinische UniversitΓ€t in Berlin, Germany, from 2005 to 2006. She also worked as a Senior Research Fellow at IVAX Drug Research Institute from 2003 to 2007 and held a Max Planck Fellowship at the Max-Planck Institute fΓΌr neurologische Forschung in Cologne, Germany, from 2000 to 2003. Her earlier positions include Senior Research Fellow roles at Sanofi-Synthelabo Chinoin from 1997 to 2000 and Biorex R&D Co. from 1995 to 1997. She began her career as a Research Fellow at the Institute for Drug Research from 1990 to 1995 and as a Junior Research Fellow at the same institute from 1987 to 1990.

Publication Top Notes:

1.Fluid Dynamics Optimization of Microfluidic Diffusion Systems for Assessment of Transdermal Drug Delivery: An Experimental and Simulation Study

  • Journal: Scientia Pharmaceutica
  • Publication Date: June 2024

2. Progress in Topical and Transdermal Drug Delivery Researchβ€”Focus on Nanoformulations

  • Journal: Pharmaceutics
  • Publication Date: June 2024

3. Transdermal Delivery of Ξ±-Aminophosphonates as Semisolid Formulationsβ€”An In Vitro-Ex Vivo Study

  • Journal: Pharmaceutics
  • Publication Date: May 2023

 

 

Assoc. Prof. Dr. Kyeong Soo Kim | Pharmaceutics Awards | Excellence in Research

Posted on by ScienceFather

Assoc. Prof. Dr. Kyeong Soo Kim | Pharmaceutics Awards | Excellence in Research

Assoc. Prof. Dr. Kyeong Soo KimΒ  , Gyongsang National University/Dept. of Pharmaceutical Engineering , South Korea

Kyeong Soo Kim is an accomplished researcher and academic based in the Republic of Korea. He currently serves as an Associate Professor in the Department of Pharmaceutical Engineering at Gyeongsang National University. Dr. Kim earned his Ph.D. in Pharmacy from Hanyang University, where he specialized in the development of novel controlled release formulations for fenofibric acid. His research interests span nanotechnology applications for poorly water-soluble drugs, improved pharmaceutical technologies for controlled release dosage forms, inhaled drug delivery systems, and dermal drug delivery systems. Prior to his current position, he held roles as a Postdoctoral Research Associate at the University of Mississippi and as a Principal Scientist at Hanmi Pharm. Co., Ltd., where he gained extensive experience in formulation and process development. Dr. Kim’s expertise includes designing oral and parenteral dosage forms, conducting preformulation studies, and utilizing advanced techniques such as solid dispersion, spray drying, and lipid-based formulations to enhance drug delivery efficacy. He is actively involved in research and has contributed significantly to the field through his publications and professional engagements.

Professional Profile:

Scopus

πŸŽ“Education:

Kyeong Soo Kim is a distinguished academic and researcher in the field of pharmacy, currently holding the position of Associate Professor at Gyeongsang National University in the Republic of Korea. He completed his Ph.D. in Pharmacy at Hanyang University from March 2011 to August 2015, under the guidance of Professor Han-Gon Choi, Ph.D. His doctoral research focused on the development of innovative controlled release formulations for fenofibric acid. Prior to his doctoral studies, he earned a Master of Science in Pharmacy at Chungbuk National University from March 2002 to August 2004, where his research investigated the depigmenting effects and mechanisms of piperlonguminine derived from Piper longum. Kyeong Soo Kim began his academic journey with a Bachelor of Science in Pharmacy, also from Chungbuk National University, completed from March 1998 to February 2002. His educational background underscores his expertise in pharmaceutical sciences, particularly in drug delivery systems and formulation development.

 🏒Work Experience:

Kyeong Soo Kim is currently an Associate Professor in the Department of Pharmaceutical Engineering at Gyeongsang National University in the Republic of Korea, a position he has held since September 2017. Prior to joining Gyeongsang National University, Dr. Kim served as a Postdoctoral Research Associate at the Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, USA, from September 2016 to August 2017. Before his time in the United States, he worked as a Postdoctoral Research Fellow at the Laboratory of Industrial & Physical Pharmacy at Hanyang University, Republic of Korea, from September 2015 to August 2016. Dr. Kim’s extensive professional experience also includes a significant tenure as a Principal Scientist and Team Manager at the Pharmaceutical R&D Center of Hanmi Pharm. Co., Ltd., Republic of Korea, where he contributed from August 2004 to November 2014. His career path highlights his expertise in pharmaceutical engineering, drug delivery systems, and research leadership in both academic and industrial settings.

Publication Top Notes:

  • “Improved bioavailability and high photostability of methotrexate by spray-dried surface-attached solid dispersion with an aqueous medium” by Giri, B.R., Kim, J.S., Park, J.H., … Choi, H.G., Kim, D.W.
    • Journal: Pharmaceutics, 2021, 13(1), pp. 1–14, 111
    • Citations: 36
  • “Nitration of protein phosphatase 2A increases via Epac1/PLCΞ΅/CaMKII/HDAC5/iNOS cascade in human endometrial stromal cell decidualization” by Lee, S.Y., Lee, Y.Y., Choi, J.-S., … Park, S.-Y., Han, J.-S.
    • Journal: FASEB Journal, 2020, 34(11), pp. 14407–14423
    • Citations: 2
  • “Development of Novel d-Cycloserine Tablet with Improvement of Drug Stability and Dissolution-Equivalence to the d-Cycloserine-Loaded Commercial Hard Capsule” by Kim, J.S., Choi, Y.J., Woo, M.R., … Jin, S.G., Choi, H.-G.
    • Journal: Bulletin of the Korean Chemical Society, 2020, 41(6), pp. 603–608
    • Citations: 3
  • “Enhanced Chemical Stability of D-Cycloserine via Tablet Form Containing Magnesium Oxide as an Alkali Stabilizer” by Kim, J.S., Lee, S.M., Kim, D.S., … Jin, S.G., Choi, H.-G.
    • Journal: Bulletin of the Korean Chemical Society, 2020, 41(1), pp. 10–14
    • Citations: 1
  • “Self-microemulsifying drug delivery system (SMEDDS) for improved oral delivery and photostability of methotrexate” by Kim, D.S., Cho, J.H., Park, J.H., … Choi, H.-G., Kim, D.W.
    • Journal: International Journal of Nanomedicine, 2019, 14, pp. 4949–4960
    • Citations: 61